1
|
Best MP, Straw RC, Gumpel E, Fry DR. Long-term remission and survival in dogs with high-grade, B cell lymphoma treated with chemotherapy with or without sequential low-dose rate half-body irradiation. J Vet Intern Med 2023; 37:2368-2374. [PMID: 37700548 PMCID: PMC10658474 DOI: 10.1111/jvim.16840] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2022] [Accepted: 08/21/2023] [Indexed: 09/14/2023] Open
Abstract
BACKGROUND Standard of care for dogs with high-grade lymphoma, multiagent chemotherapy, achieves good initial responses but long-term remissions are infrequent; previous studies using half-body irradiation suggest improved long-term outcomes. HYPOTHESIS The addition of low-dose rate half-body irradiation would improve outcomes in dogs with B-cell lymphoma. ANIMALS Client-owned dogs with stage III or higher, substage a, B-cell lymphoma that achieved complete remission after 4 doses of multiagent chemotherapy. METHODS A case-controlled design comparing 2-year remission and survival rates between dogs treated with CHOP-based chemotherapy and those treated with chemotherapy and sequential low-dose rate half-body irradiation. RESULTS Thirty-eight dogs were enrolled with 18 included in final analysis, 9 prospectively-enrolled dogs and 9 case-matched historical controls. The irradiation cohort's 2-year disease-free rate was 56% whereas median duration exceeded the 730-day study period compared with 0% and 261 days in the chemotherapy only group. Remission duration significantly differed between cohorts (P < .01), hazard ratio 0.218 (95% CI: 0.06-0.77). The irradiation cohort's 2-year survival rate was 78% with median overall survival duration exceeding the 730 day study period compared with 11% and 286 days in the chemotherapy only group. Overall survival time significantly differed between cohorts (P < .02), hazard ratio 0.173 (95% CI: 0.03-0.839). CONCLUSIONS AND CLINICAL IMPORTANCE The improved long-term outcome achieved by dogs administered sequential low-dose rate half-body irradiation in this study is similar to previous observational studies. Where long-term remission is sought in dogs with B-cell lymphoma low-dose rate half-body irradiation could be considered in addition to standard chemotherapy.
Collapse
Affiliation(s)
| | - Rod C. Straw
- Brisbane Veterinary Specialist CentreBrisbaneQueenslandAustralia
- The Australian Animal Cancer FoundationAlbany CreekQueenslandAustralia
| | - Elias Gumpel
- Small Animal Specialist HospitalNorth RydeNew South WalesAustralia
| | - Darren R. Fry
- Brisbane Veterinary Specialist CentreBrisbaneQueenslandAustralia
| |
Collapse
|
2
|
|
3
|
Nagata K, McHale B, Sladakovic I, Gutti JR, Mayer J. TOTAL BODY IRRADIATION FOR THE TREATMENT OF LYMPHOMA IN A GUINEA PIG (CAVIA PORCELLUS). J Exot Pet Med 2019. [DOI: 10.1053/j.jepm.2018.02.043] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
4
|
Smith AA, Lejeune A, Kow K, Milner RJ, Souza CH. Clinical Response and Adverse Event Profile of Bleomycin Chemotherapy for Canine Multicentric Lymphoma. J Am Anim Hosp Assoc 2017; 53:128-134. [DOI: 10.5326/jaaha-ms-6598] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
ABSTRACT
Although canine multicentric lymphoma is initially responsive to multidrug chemotherapy, resistance and relapse create a need for novel chemotherapeutics. Bleomycin is an antitumor antibiotic with a minimal adverse event profile; though commonly used for human non-Hodgkin's lymphoma, its use is poorly characterized in dogs. The purpose of this retrospective case series was to describe the clinical response and adverse event profile of systemic bleomycin for canine multicentric lymphoma (n = 10). A partial response was noted in one dog that died 24 days later due to unrelated disease. Adverse events were infrequent and limited to grade 1 gastrointestinal and grade 1 constitutional toxicity. Although clinical response was minimal, systemic bleomycin was well tolerated when administered at 0.5 U/kg. Additional studies are warranted to determine the influence of administration schedule and dose on the efficacy of bleomycin for veterinary neoplasia.
Collapse
Affiliation(s)
- Ashley A. Smith
- From the Department of Small Animal Clinical Sciences, College of Veterinary Medicine, Auburn University, Auburn, Alabama (A.A.S.); Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Gainesville, Florida (A.L., C.H.M.S., R.J.M.); and Fitzpatrick Referrals, Godalming, Surrey, United Kingdom (K.K.)
| | - Amandine Lejeune
- From the Department of Small Animal Clinical Sciences, College of Veterinary Medicine, Auburn University, Auburn, Alabama (A.A.S.); Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Gainesville, Florida (A.L., C.H.M.S., R.J.M.); and Fitzpatrick Referrals, Godalming, Surrey, United Kingdom (K.K.)
| | - Kelvin Kow
- From the Department of Small Animal Clinical Sciences, College of Veterinary Medicine, Auburn University, Auburn, Alabama (A.A.S.); Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Gainesville, Florida (A.L., C.H.M.S., R.J.M.); and Fitzpatrick Referrals, Godalming, Surrey, United Kingdom (K.K.)
| | - Rowan J. Milner
- From the Department of Small Animal Clinical Sciences, College of Veterinary Medicine, Auburn University, Auburn, Alabama (A.A.S.); Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Gainesville, Florida (A.L., C.H.M.S., R.J.M.); and Fitzpatrick Referrals, Godalming, Surrey, United Kingdom (K.K.)
| | - Carlos H.M. Souza
- From the Department of Small Animal Clinical Sciences, College of Veterinary Medicine, Auburn University, Auburn, Alabama (A.A.S.); Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Gainesville, Florida (A.L., C.H.M.S., R.J.M.); and Fitzpatrick Referrals, Godalming, Surrey, United Kingdom (K.K.)
| |
Collapse
|
5
|
Richards KL, Suter SE. Man's best friend: what can pet dogs teach us about non-Hodgkin's lymphoma? Immunol Rev 2015; 263:173-91. [PMID: 25510277 DOI: 10.1111/imr.12238] [Citation(s) in RCA: 57] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
Animal models are essential for understanding lymphoma biology and testing new treatments prior to human studies. Spontaneously arising lymphomas in pet dogs represent an underutilized resource that could be used to complement current mouse lymphoma models, which do not adequately represent all aspects of the human disease. Canine lymphoma resembles human lymphoma in many important ways, including characteristic translocations and molecular abnormalities and similar therapeutic responses to chemotherapy, radiation, and newer targeted therapies (e.g. ibrutinib). Given the large number of pet dogs and high incidence of lymphoma, particularly in susceptible breeds, dogs represent a largely untapped resource for advancing the understanding and treatment of human lymphoma. This review highlights similarities in molecular biology, diagnosis, treatment, and outcomes between human and canine lymphoma. It also describes resources that are currently available to study canine lymphoma, advantages to be gained by exploiting the genetic breed structure in dogs, and current and future challenges and opportunities to take full advantage of this resource for lymphoma studies.
Collapse
Affiliation(s)
- Kristy L Richards
- Center for Comparative Medicine and Translational Research, North Carolina State University, Raleigh, NC, USA; Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA; Division of Hematology/Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
| | | |
Collapse
|
6
|
Hematopoietic Tumors. WITHROW AND MACEWEN'S SMALL ANIMAL CLINICAL ONCOLOGY 2013. [PMCID: PMC7161412 DOI: 10.1016/b978-1-4377-2362-5.00032-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
7
|
Clermont T, Leblanc AK, Adams WH, Leblanc CJ, Bartges JW. Radiotherapy-induced myelosuppression in dogs: 103 cases (2002-2006). Vet Comp Oncol 2011; 10:24-32. [PMID: 22236056 DOI: 10.1111/j.1476-5829.2011.00271.x] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Definitive radiotherapy refers to delivery of large doses, typically 48-62 Gray, of ionizing radiation over several weeks using a daily or alternate-day fractionation schedule. The impact of definitive radiotherapy alone on haematopoiesis in tumour-bearing dogs is unknown. Medical records from 103 dogs receiving definitive (60) Cobalt teletherapy for cancer over a 5-year period were reviewed for signalment, tumour type and location, total radiotherapy dose and fractionation scheme. Complete blood count data were collected before, halfway through, and at the end of radiation treatment, and analysed for changes associated with patient variables. The results demonstrate significant reductions in haematocrit, total white blood cell count, neutrophils, eosinophils, monocytes, lymphocytes and platelets occurred during definitive radiotherapy but remained within laboratory reference intervals. These data are important for anticipation of toxicity associated with combinations of radiotherapy and chemotherapy in dogs but do not support the routine monitoring of haematology parameters during definitive radiotherapy.
Collapse
Affiliation(s)
- T Clermont
- Department of Small Animal Clinical Sciences, University of Tennessee College of Veterinary Medicine, Knoxville, TN37996, USA
| | | | | | | | | |
Collapse
|
8
|
Parshley DL, LaRue SM, Kitchell B, Heller D, Dhaliwal RS. Abdominal irradiation as a rescue therapy for feline gastrointestinal lymphoma: A retrospective study of 11 cats (2001–2008). J Feline Med Surg 2011; 13:63-8. [DOI: 10.1016/j.jfms.2010.07.017] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/20/2010] [Indexed: 10/18/2022]
Abstract
In this retrospective study medical records of 11 cats with gastrointestinal lymphoma were evaluated to determine the efficacy of radiation therapy when used in a rescue therapy setting. All cats had relapsed or resistant lymphoma. Two fractions of radiation were delivered over 2 days for a total of 800 cGy. Acute effects of radiation were not noted, except one cat that had a self-limiting loss of appetite. Response was noted in 10/11 cats. Median survival post-radiation therapy was 214 days and the overall median survival in this study was 355 days. This study suggests that abdominal irradiation for feline gastrointestinal lymphoma was well tolerated and may contribute to a positive clinical response.
Collapse
Affiliation(s)
- Dorothy L. Parshley
- All Care Animal Referral Center, Fountain Valley, CA 92708, United States
- Center for Comparative Oncology, Michigan State University, East Lansing, MI 48823, United States
- Olympia Veterinary Cancer Center, 3011 Pacific Avenue NE, Olympia, WA 98501, United States
| | - Susan M. LaRue
- Animal Cancer Center James L. Voss Veterinary Teaching Hospital, Colorado State University, Fort Collins, CO, United States
| | - Barbara Kitchell
- All Care Animal Referral Center, Fountain Valley, CA 92708, United States
- Center for Comparative Oncology, Michigan State University, East Lansing, MI 48823, United States
| | - David Heller
- All Care Animal Referral Center, Fountain Valley, CA 92708, United States
- Advanced Veterinary Care Center, 15926 Hawthorne Blvd. Lawndale, CA 90260, United States
| | - Ravinder S. Dhaliwal
- All Care Animal Referral Center, Fountain Valley, CA 92708, United States
- PetCare Veterinary Hospital, Santa Rosa, CA 95401, United States
| |
Collapse
|
9
|
Husbands BD, McNiel EA, Modiano JF. Initial evaluation of safety of wide-field irradiation in the treatment of hematopoietic neoplasia in the cat. Vet Radiol Ultrasound 2010; 51:688-96. [PMID: 21158248 DOI: 10.1111/j.1740-8261.2010.01728.x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
Localized radiation therapy is well tolerated in cats with confined tumors; however, the use of wide-field radiation therapy to treat disseminated neoplasia has not been evaluated systematically in this species. Wide-field external beam radiation therapy, which we define as irradiation of cranial or caudal halves of the body either individually or sequentially, was undertaken as an experimental option to treat cats with either chemotherapy-refractory or naive hematopoietic neoplasia considered to have a poor prognosis. Fifteen cats with hematopoietic malignancies received wide-field external beam radiation therapy between 2003 and 2006. Cats received 8 Gy delivered in 4 Gy fractions with 60Co photons. Treatment-related toxicity was scored according to criteria established by the Veterinary Cooperative Oncology Group. Animals without preexisting abnormalities on hemograms exhibited no or mild (Grade 1 or 2) hematopoietic toxicity. Although most cats (14 of 15) had preexisting gastrointestinal (GI) signs, these signs were stable (29%) or improved (42%) following irradiation. Worsening GI signs following irradiation occurred transiently in two cats and in association with progressive disease in two others. No pulmonary, renal, hepatic, or dermatologic toxicities were detected. In summary, wide-field external beam radiation therapy can be administered safely to, and may provide therapeutic benefit for, cats with disseminated hematopoietic neoplasia.
Collapse
Affiliation(s)
- Brian D Husbands
- Veterinary Medical Center, College of Veterinary Medicine, University of Minnesota, St. Paul, MN 55108, USA.
| | | | | |
Collapse
|
10
|
Lurie D, Gordon I, Théon A, Rodriguez C, Suter S, Kent M. Sequential Low-Dose Rate Half-Body Irradiation and Chemotherapy for the Treatment of Canine Multicentric Lymphoma. J Vet Intern Med 2009; 23:1064-70. [DOI: 10.1111/j.1939-1676.2009.0353.x] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|